Objective: Advantages of thoracoscopic lobectomy for early stage non-small cell lung cancer (NSCLC) include less postoperative pain, earlier pulmonary rehabilitation and shorter length of hospitalization. The authors assess the results of thoracoscopic lobectomy for non-small cell lung cancer in stage I, II. Subject and method: A prospective database of 47 consecutive patients who underwent thoracoscopic lobectomy between March 2010 and December 2013 was queried. Demographic, histopathologic, perioperative and outcome variables were assessed using standard descriptive statistics and Kaplan-Meier survival analyses. Result: Of the 47 patients undergoing planed thoracoscopic lobectomy, 40 patients (85.1 percent) had a completed thoracoscopic lobectomy, 6 patients (12.8 percent) had a video- assisted thoracoscopic lobectomy and 1 patient (2.1 percent) underwent conversion to thoracotomy. Among the 47 patients with NSCLC, pathologic analysis demonstrated stage I in 34 patients (72.3 percent), stage II in 13 patients (27.7 percent). The operative and perioperative (30-day) mortality was 0 percent, similarly. Postoperative pulmonary function was normal in all patients. The overall 34-month survival rate for the entire cohort was 78.1 percent, and the 36-month overall survival rates for stage I NSCLC, stage II NSCLC were 96.9 percent, 66.7 percent, respectively. Conclusion: Thoracoscopic lobectomy is applicable to early stage non-small cell lung cancer and is associated with a low perioperative morbidity and mortality rate.
- Đăng nhập để gửi ý kiến